pac Flashcards
PNS mechanism
Ach from CNS/brain neurons - on Nicotinic receptors N - postganglionic fiber release Ach - M3 on exocrine glands & M3 smooth muscle & M2 heart/ muscarinic receptor
Muscarinic receptor
M2 on heart - G-protein coupled receptor -for Ach
cholinergic synapse
Ach release
SNS mechanism
Ach from CNS/ spinal cord neurons -
neuronal Nicotinic Nn receptors on post ganglion - release NE - on the Alpha-1 R on smooth muscle & beta-1 R on heart
N R on adrenal medulla - releasing N and NE in blood
NE = NA
NorEpinephrine = NorAdrenaline
Nicotinic receptors subtypes
Nn - nicotinic subtype - the postganglionic neuron - SNS &
Nm - muscle subtype -somatic
autonomic nervous system
Ach from pre-synaptic - cholinergic - on Nn & muscarinic R & AChe & presynaptic autoreceptor
somatic nervous system
spinal cord - somatic nerves - Ach - Nm on skeletal muscle
AChe
primary Ach break down = acetate + choline
cholinergic synapse
where the Ach is released
primary breakdown methods -
NE = uptake to presynaptic neuron - Catechol-O-methyl-transferase ACh = AChE - enzyme
adrenergic transmission
alpha-beta R
presynaptic autoreceptors
primary -reuptake into nerve terminal - catechol-o-methyl-transferase
uptake to tissue - monoamine oxidase MAO
NE making
Tyrosine - DOPA -dopamine - NE
ANS tone
basal level of activity (basic life function) - parasympathetic or sympathetic
organs with single system control - SNS
adrenal gland- release EP
blood vessels - vasoconstriction - gut, skin - Alpha 1 R
blood vessel - vasodilation - skeletal muscle - beta 2 R
heart rate PNS vs SNS
inc - SNP - beta 1 R by NE
dec - PNS - muscarinic M2 R by Ach
respiratory bronchi SNS vs PNS
SNS - bronchodilation - beta 2 R
PNS - bronchoconstriction -
beta 2 receptor
SNS - dilation of vessel and bronchi
drugs used for myasthenia gravis and Alzheimers
cholinesterase inhibitors
ATROPINE
non-selectiv muscarinic antagonist
M2 receptor
GCPR - activates Gi [inhibitory G protein] - dec cAMP
nicotinic antagonist use
in surgery - intubation - relaxing muscle
beta2-Receptor
treating asthma - dilate bronchi
alpha 2 receptor
feedback inhibition - dec NE release
alpha 1 R
GPCR - acting through Gq - inc Ca - vasoconstriction - inc BP
beta 1 R
GPCR - Gs - inc cAMP - inc Ca - inc Heart force rate
alpha 1 agonist
vasoconstriction - inc BP
dilate pupil
COCAINE
blocking NE reuptake
AMPHETAMINE
release NE from terminal
PRAZOSIN
alpha 1 antagonist - dec BP
propranolol
beta 1, 2 antagonist - hypertension, angima, arrhythmia, heart failure
lipoprotein[lipid protein complex] classes
chylomicron VLDL LDL HDL (high-low size / triglyceride trend)
highest TG
chylomicrons
highest CHOL
how
LDL
get most of CHOL of VLDL
bad cholesterol
hepatic cholesterol
biosynthesis
catabolism
Acetyl CoA - HMG-CoA - HMG-CoA reductase/rate limiting - cholesterol (can also be secret to bile as cholesterol) bile acid (secreted to bile)
chylomicrons mechanism
intestine - dietary lipid - LPL / capillary endothelial cells lipolysis – Fas - tissue - energy utilization / oxidation & energy storage / triglyceride biosynthesis
remnants - liver endocytosis
lipoprotein with;
majority of serum triglyceride
most TG
VLDL
Chylomicron
VLDL mechanism
liver - LPL lipolysis / capillary peripheral tissue - Fas - tissue - energy storage and utilization
remanent VHDL = IDL - removal of apolipoprotein & lipolysis of triglyceride - LDL / blood
intermediate density lipoprotein
IDL is the VLDL remanent
LDL
from the IDL - LDL - peripheral tissue + 50% liver /endocytosis
immature HDL
apolipoproteins [ApoAI, ApoAll] + phospholipids
HDL
liver - HDL immature - during VLDL & chylomicrons lipolysis get lipid/cholesterol + get cholesterol from peripheral tissue - uptake by SR-BI - liver - bile acid - bile / or can directly from cholesterol add to bile - excursion
bad
good
cholesterol
LDL
HDL
hyperlipoproteinemias
heterogenous group of disorders
can be monogenic , polygenic/common,
differ based on cause, lipoprotein affected, cholesterol and most important their CVD risk increase
hyperlipoproteinemias
based on the lipoprotein affected determine which lipid will elevate in blood
hypercholesterolemia
hypertriglyceridemia
mixed hyperlipidemia
major inc in;
LDL
VLDL
VLDL + LDL
disease associated with high cholesterol = high CVD
bad cholesterol = LDL
hypercholesterolemia
hyperlipidemia
treatments for the CVD
achieve lower LDL cholesterol l
atherosclerosis
red blood flow
CVD, stroke, kidney failure
severity with again genetic
high LDL - primary risk factor
atherosclerosis risk relation
+ LDL:HDL, total cholesterol, LDL
- HDL / inverse cholesterol transport mechanism
TLC
Therapeutic life style change
10-30% LDL red
statin
open lactose ring
competitive inhibitor of HMG CoA reductase
primary action = inc hepatocyte LDL receptors -